Table 2.
List of mRNA Up-regulated by the TAM2 Subset (Myeloid Cells Scoring Gr1lowMHCIIlow), but No Longer Up-regulated Upon Treatment With the CCL2i Subjected for Biocarta-Based Gene Group Analysis
| Gene symbol | Full name |
|---|---|
| Abcb1a | ATP-binding cassette, subfamily B (MDR/TAP), member 1A |
| Btnl1 | Butyrophilin-like 1 |
| C2 | Complement component 2 (within H-2S) |
| C4bp | Complement component 4 binding protein |
| C7 | Complement component 7 |
| C8b | Complement component 8, β polypeptide |
| Ccl26 | Chemokine (C-C motif) ligand 26 |
| Ccr6 | Chemokine (C-C motif) receptor 6 |
| Cd209g | CD209g antigen |
| Cd27 | CD27 antigen |
| Cd5 | CD5 antigen |
| Cd53 | CD53 antigen |
| Cd6 | CD6 antigen |
| Cd96 | CD96 antigen |
| Csf3r | Colony stimulating factor 3 receptor (granulocyte) |
| Cxcl11 | Chemokine (C-X-C motif) ligand 11 |
| Cxcr1 | Chemokine (C-X-C motif) receptor 1 |
| Cxcr2 | Chemokine (C-X-C motif) receptor 2 |
| Eomes | Eomesodermin |
| Fasl | Fas ligand (TNF superfamily, member 6) |
| Folr4 | IZUMO1 receptor, JUNO |
| Foxp3 | Forkhead box P3 |
| Frmpd4 | FERM and PDZ domain containing 4 |
| Gp1bb | Glycoprotein Ib, β polypeptide |
| Gzma | Granzyme A |
| H2-Q10 | Histocompatibility 2, Q region locus 10 |
| Icam4 | Intercellular adhesion molecule 4, Landsteiner–Wiener blood group |
| Icam5 | Intercellular adhesion molecule 5, telencephalin |
| Ifitm1 | Interferon-induced transmembrane protein 1 |
| Ifna1 | Interferon α1 |
| Il17a | Interleukin 17A |
| Il18r1 | Interleukin 18 receptor 1 |
| Il18rap | Interleukin 18 receptor accessory protein |
| Il1b | Interleukin 1β |
| Il1r1 | Interleukin 1 receptor, type I |
| Il1r2 | Interleukin 1 receptor, type II |
| Il1rap | Interleukin 1 receptor accessory protein |
| Il21 | Interleukin 21 |
| Il22 | Interleukin 22 |
| Il22ra2 | Interleukin 22 receptor, α 2 |
| Il23a | Interleukin 23, α subunit p19 |
| Il2ra | Interleukin 2 receptor, α chain |
| Il3 | Interleukin 3 |
| Il33 | Interleukin 3 |
| Il9 | Interleukin 9 |
| Itln1 | Intelectin 1 (galactofuranose binding) |
| Kir3dl1 | Killer cell immunoglobulin-like receptor, 3 domains, long cytoplasmic tail, 1 |
| Klra21 | Killer cell lectin-like receptor subfamily A, member 21 |
| Klra5 | Killer cell lectin-like receptor, subfamily A, member 5 |
| Klra6 | Killer cell lectin-like receptor, subfamily A, member 6 |
| Klra8 | Killer cell lectin-like receptor, subfamily A, member 8 |
| Lef1 | Lymphoid enhancer binding factor 1 |
| Masp1 | Mannan-binding lectin serine peptidase 1 |
| Masp2 | Mannan-binding lectin serine peptidase 2 |
| Pla2g2e | Phospholipase A2, group IIE |
| Psmb11 | Proteasome (prosome, macropain) subunit, β type, 11 |
| Rag2 | Recombination activating gene 2 |
| S100a8 | S100 calcium binding protein A8 (calgranulin A) |
| S100a9 | S100 calcium binding protein A9 (calgranulin B) |
| Sele | Selectin, endothelial cell |
| Tnfrsf9 | Tumor necrosis factor receptor superfamily, member 9 |
| Tnfsf15 | Tumor necrosis factor (ligand) superfamily, member 15 |
| Trem1 | Triggering receptor expressed on myeloid cells 1 |
| Xcl1 | Chemokine (C motif) ligand 1 |
NOTE. Mice at 14 days of age received DEN and twice-weekly injections of CCl4 for 16 weeks. In addition, mice were treated with CCL2i mNOXE36 or control inhibitor (revCCL2i) 3 times/wk subcutaneously. Peritumoral hepatic myeloid cells were isolated and subjected to quantitative analysis of mRNA expression (Nanostring immunology kit).
ATP, adenosine triphosphate; IZUMO1, Izumo sperm-egg fusion 1; JUNO, folate receptor 4, folate receptor delta or IZUMO1R; MDR, multidrug resistance; TNF, tumor necrosis factor.